Neurology

• 

  People

  • Administrative Positions

    • O'Brien, Richard J, Chair, Department of Neurology

  • Professorships

    • O'Brien, Richard J, Disque D. Deane University Distinguished Professor of Neurology

  • Primary Appointments

    • Akkari, Patrick Anthony, Adjunct Professor in the Department of Neurology
    • Hurwitz, Barrie James, Associate Professor Emeritus of Medicine
    • Matthew, William Dean, Adjunct Professor in the Department of Neurology
    • O'Brien, Richard J, Professor of Neurology
    • Rozear, Marvin Price, Associate Professor Emeritus of Medicine
    • Tourian, Ara Y., Associate Professor Emeritus of Medicine

  • Secondary Appointments

    • O'Brien, Emily, Assistant Professor in Neurology
    • O'Brien, Emily, Associate Professor in Neurology
    • Peters, Katherine Barnett, Associate Professor in Neurology
    • Railey, Kenyon Michael, Assistant Professor in Neurology
    • Smith, Edward Clinton, Associate Professor of Neurology

  • Joint Appointments

    • Segura, Tatiana, Professor in Neurology

  • Non-Faculty Positions

    • Gupta, Rupali, Postdoctoral Associate
• 

  Administers Grant

  • A Consensus Conference on Treatment Guidelines for Myasthenia Gravis (ad hoc)
  • A DB, Randomized, Placebo Controlled, Parallel Group Study to Qualify a Biomarker Algorithm for Risk of Developing MCI due to AD and to Test the S&E of Pioglitazone (AD-4833 SR 0.8 mg QD) Delay Onset of MCI due AD in Cognitively Normal Subjects.
  • A Mouse Model of Inflammation in Alzheimer's Disease
  • A PHASE 2B/3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12 MONTH CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF MN-166 (IBUDILAST) FOLLOWED BY AN OPEN-LABEL EXTENSION IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS
  • A Phase 1b Multicenter, Open-Label, Single Ascending Dose Study to Evaluate the Safety and Tolerability of PF-06939926 in Ambulatory Subjects with Duchenne Muscular Dystrophy" Protocol # C3391001 (hereinafter the "Study")
  • A Phase 2 Pharmacodynamic Study of Ezogabine on Neuronal Excitability in Amyotrophic Lateral Sclerosis
  • A Phase 2 Randomized, Double Blind, Placebo-Controlled, Multiple Ascending dose study to evaluate Safety,Efficacy, and Pharmacokinetics and Pharmacodynamics of PF 06252616 in Ambulatory boys with Duchenne Muscular Dystrophy.
  • A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects with Amyotrophic Lateral Sclerosis (ALS) and Evidence of Elevated Systemic Inflammation
  • A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerabiliity and Efficacy of Tirasemtiv in Patients with Amyotrophic Lateral Sclerosis ( ALS)
  • A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients with Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY -ALS (CY 4031)
  • A Phase II, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NS-065/NCNP-01 in Boys with Duchenne Muscular Dystrophy (DMD)
  • A Pilot Trial of Triheptanoin for People with Amyotrophic Lateral Sclerosis (PALS)
  • A Randomized,Cross-Over,Controlled Feasibililty and Validation Study of a Self-Adminstered Memory Screening Test with Automated Reporting(SAMSTAR) inNormal Control subjects and Subjects with MCI, age 55-84
  • ALS Telemedicine
  • ALS Telemedicine
  • An Open label, Long Term Safety Study of SD-809 Er in Subjects wtih Chorea associated with Huntington's Disease.
  • An open-label extension study of the long-term safety, tolerability and efficacy of drisapersen in US and Canadian subjects with Duchenne Muscular Dystrophy.
  • Bilateral Brain Dynamics Supporting Cognition in Normal Aging and Dementia
  • Biomedical Researcher Development Scholarship (BRDS) Research Career Development Award (K12)
  • Characterization of total body muscle mass and muscle protein fractional synthesis rate in boys with Duchenne muscular dystrophy
  • Clinical Protocol for a Phase II Open-label, Multicenter Long-term Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys with Duchenne Muscular Dystrophy (DMD)
  • Clinical Research in ALS & Related Disorders for Therapeutic Development (CREATE)
  • Copy Number Alterations in Low Mutation Cancer
  • Cross-validation of LRRK2 biomarkers
  • Development of a Novel Model for Tourettes Syndrome
  • Duke ALS Telemedicine Clinic
  • EFFECTS OF ORAL LEVOSIMENDAN (ODM-109) ON RESPIRATORY FUNCTION IN PATIENTS WITH ALS: OPEN-LABEL EXTENSION FOR PATIENTS COMPLETING STUDY 3119002
  • Efficacy of Nido Drug Compound BF3 in an animal model of SBMA
  • ExtracorPoreal FILtration of Subarachnoid Hemorrhage via SpinaL CAtheteR EXTension (PILLAR-XT)
  • FLARE Feasibility Study on Laser Thermal Therapy Ablation for the treatment of Medically Refractory Epilepsy
  • HDE Post-Approval Study (PAS) of NeuRx DPS for ALS
  • Healey ALS Platform Trial Open Label Extension Zilucoplan
  • IPA - John F Ervin
  • IPA-Richard Lawrence Whitley
  • Identification of diagnostic peptides for the detection of sporadic amyotrophic lateral sclerosis (sALS)
  • Integrated Genomics in Clinical ALS (GTAC)
  • Interactions between the immune system, genetics and environmental mitochondrial toxicants in models of Parkinson's disease
  • LRRK2 kinase activity and mitochondrial DNA damage in Parkinson's disease
  • MULTICENTER 1-YEAR OBSERVATIONAL STUDY OF PATIENTS WHO ARE INITIATING BRIVARACETAM
  • MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY OF PF-06252616 IN BOYS WITH DUCHENNE MUSCULAR DYSTROPHY
  • Masticatory sensitization of trigeminal ganglion sensory neurons
  • Mechanisms of mitochondrial genome integrity in familial and idiopathic Parkinson's disease
  • Mechanisms of pathogenesis in LRRK2-related Parkinson's disease
  • Mitochondrial DNA damage as a blood-based biomarker of early Parkinson's disease
  • Mitochondrial DNA damage in PD and control in a pesticide-exposed cohort
  • Mitochondrial DNA damage in brain and blood in Alzheimer's disease
  • Mitochondrial DNA damage: screening tool and novel therapeutic target for Parkinson's disease
  • NUVA . IGA 1501-1502-1503
  • North Carolina Regional Consortium for Brain Health in Aging
  • PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTIPLE DOSE STUDY OF CK-2127107 IN TWO ASCENDING DOSE COHORTS OF PATIENTS WITH SPINAL MUSCULAR ATROPHY (SMA)
  • Protocol CY 5022: A PHASE 2, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, DOSE-RANGING, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF CK-2127107 IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS)
  • Sponsored Research Agreement (Non-Clinical)
  • Supplement: Mitochondrial DNA damage as a blood-based biomarker of early Parkinson's disease
  • The Anti-Aging Role of Klotho in Skeletal Muscle Regeneration
  • The Duke ALS Association Certified Center
  • Using network-guided TMS to ameliorate memory deficits in early Alzheimer's disease

• Sub-Organizations

Add data to my Website